Understand the source comparison
Peptides for ADHD Treatment Protocol Evidence Guide: Comparison
| Peptide | Mechanism of Action | Strongest Evidence Base | Administration Route | Dosing Protocol (Published) | ADHD-Specific Data | Professional Assessment ||—|—|—|—|—|—|| Cerebrolysin | BDNF/NGF upregulation, NMDA modulation | RCTs in vascular dementia, TBI
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Peptide | Mechanism of Action | Strongest Evidence Base | Administration Route | Dosing Protocol (Published) | ADHD-Specific Data | Professional Assessment ||—|—|—|—|—|—|| Cerebrolysin | BDNF/NGF upregulation, NMDA modulation | RCTs in vascular dementia, TBI cognitive recovery | Intramuscular injection | 30–60mL, 5 days/week, 4–8 weeks | None—cognitive outcomes in TBI/dementia only | Strongest clinical evidence for cognitive improvement, but mechanism timelines (weeks) don't match stimulant pharmacokinetics (hours); requires clinical administration || Dihexa | HGF receptor agonism, synaptogenesis | Preclinical rodent spatial learning | Oral (animal models) | 10–50mg/kg in rats (no human equivalent established) | None—no human trials | Most potent synaptogenic activity in preclinical models, but complete absence of human safety data makes any dosing protocol speculative || P21 | Microtubule stabilization via ADNP pathway | Animal models of cognitive impairment | Intranasal | 30mcg int